Abstract:Congenital heart disease (CHD) is the most common type of developmental abnormality in humans, and is a leading cause for substantially increased morbidity and mortality in affected individuals. Increasing studies demonstrates a pivotal role of genetic defects in the pathogenesis of CHD, and presently mutations in more than 60 genes have been associated with CHD. Nevertheless, CHD is of pronounced genetic heterogeneity, and the genetic basis underpinning CHD in a large proportion of patients remains unclear. In the present study, the whole coding exons and splicing donors/acceptors of the MEF2C gene, which codes for a transcription factor essential for normal cardiovascular development, were sequenced in 200 unrelated patients affected with CHD, and a novel heterozygous missense mutation, p.L38P, was identified in an index patient with patent ductus arteriosus (PDA) and ventricular septal defect (VSD). Genetic scan of the mutation carrier's family members available showed that the mutation was present in all affected family members but absent in unaffected family members. Analysis of the proband's pedigree revealed that the mutation co-segregated with PDA, which was transmitted as an autosomal dominant trait with complete penetrance. The mutation changed the amino acid that was completely conserved evolutionarily, and did not exist in 300 unrelated, ethnically-matched healthy individuals used as controls. Functional deciphers by using a dual-luciferase reporter assay system unveiled that the mutant MEF2C protein had a significantly reduced transcriptional activity. Furthermore, the mutation significantly diminished the synergistic activation between MEF2C and GATA4, another cardiac core transcription factor that has been causally linked to CHD. In conclusion, this is the first report on the association of a MEF2C loss-of-function mutation with an increased vulnerability to CHD in humans, which provides novel insight into the molecular mechanisms underlying CHD, implying potential implications for early diagnosis and timely prophylaxis of CHD.

Role of MEF2 in Cardiac Development and Cardiovascular Diseases

The Function of the MEF2 Family of Transcription Factors in Cardiac Development, Cardiogenomics, and Direct Reprogramming

MEF2 signaling and human diseases

Myocyte Enhancer Factor 2C and Its Directly-Interacting Proteins: A Review

Requirements of Myocyte-Specific Enhancer Factor 2a in Zebrafish Cardiac Contractility

Regulation of MEF2 by p38 MAPK and its implication in cardiomyocyte biology.

Translation of Myocyte Enhancer Factor-2 is Induced by Hypertrophic Stimuli in Cardiomyocytes Through a Calcineurin-dependent Pathway.

Transcription factor MEF2A mutations in patients with coronary artery disease

The Research Progress of MEF2 Gene Family

MEF2C Loss-of-function Mutation Contributes to Congenital Heart Defects.

MEF2C mediates inhibitory effect of microRNA-214 on cardiomyocyte hypertrophy

Inhibition of MEF2A prevents hyperglycemia-induced extracellular matrix accumulation by blocking Akt and TGF-β1/Smad activation in cardiac fibroblasts

Myocyte enhancer factor 2A promotes proliferation and its inhibition attenuates myogenic differentiation via myozenin 2 in bovine skeletal muscle myoblast.

Contribution of Increased Expression of Yin Yang 2 to Development of Cardiomyopathy.

Dynamin-2 Mediates Heart Failure By Modulating Ca2+-Dependent Cardiomyocyte Apoptosis

Myocyte enhancer factor 2A delays vascular endothelial cell senescence by activating the PI3K/p-Akt/SIRT1 pathway

MEF2C loss-of-function mutation associated with familial dilated cardiomyopathy.

Role of MEF2C in the Endothelial Cells Derived from Human Induced Pluripotent Stem Cells

Bone morphogenetic protein-2 acts upstream of myocyte-specific enhancer factor 2a to control embryonic cardiac contractility.

Mutation of Mef2a in an Inherited Disorder with Features of Coronary Artery Disease

Myocyte-specific Enhancer Factor 2C: a Novel Target Gene of Mir-214-3p in Suppressing Angiotensin II-induced Cardiomyocyte Hypertrophy.